ARCHIVES

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

This article is from The Cancer Letter archive.

Vol. 31 No. 13 | April 1, 2005

Download PDF Visit The Full Archive

Related Articles

NSABP Roundup: Fisher, Pitt Negotiating; 9th Chairman Candidate

October 7, 1994

In Brief: Comprehensive Centers “Jewel In Crown” Of Cancer Program, DeVita Says; Boutwell New NCAB Member

February 18, 1983

NCI Drug Development Program Produced 7 Drugs In 10 Years, Chabner Tells Group

February 3, 1995

Sloan-Kettering Creates Paul Marks Award; Weinberg, Hong Honored By M. D. Anderson.

February 18, 2000

Oncology Practice Group Leaves Allegheny For Former Rival UPCI; Will NSABP Follow?

June 30, 2000

Also in this 8-page issue: NIH opens 240-bed Hatfield Clinical Research Center.

September 24, 2004